公开(公告)号：US12138302B2

公开(公告)日：2024-11-12

申请号：US17509110

申请日：2021-10-25

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Laurent Oliver Chorro ,  Robert George Konrad Donald ,  Jacqueline Marie Lypowy ,  Rosalind Pan

IPC: A61K39/108 ,  A61K39/00 ,  A61P31/04 ,  A61P37/04

Abstract: This invention relates to compositions that include a polypeptide derived from E. coli or a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof, and methods of use thereof.

公开(公告)号：US20220168410A1

公开(公告)日：2022-06-02

申请号：US17672126

申请日：2022-02-15

Applicant: Pfizer Inc.

Inventor： Robert G.K. Donald ,  Annaliesa Sybil Anderson ,  Laurent Oliver Chorro ,  Jianxin Gu ,  Jin-Hwan Kim ,  Srinivas Kodali ,  Jason Arnold Lotvin ,  Justin Keith Moran ,  Rosalind Pan ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Suddham Singh ,  Ling Chu ,  Scott Ellis Lomberk ,  Karen Kiyoko Takane ,  Nishith Merchant ,  Wei Chen

IPC: A61K39/108 ,  C08B37/00 ,  A61P31/04 ,  A61P37/04

Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

公开(公告)号：US20220202923A1

公开(公告)日：2022-06-30

申请号：US17554424

申请日：2021-12-17

Applicant: Pfizer Inc.

Inventor： Ye Che ,  Laurent Oliver Chorro ,  Robert George Konrad Donald ,  Matthew Curtis Griffor ,  Natalie Clare Silmon de Monerri

IPC: A61K39/108 ,  C07K14/245 ,  C07K16/12

Abstract: This disclosure relates to the design of E. coli mutated FimH polypeptides that result in improved biochemical properties and immunogenicity, compositions comprising such polypeptides, and uses thereof.

公开(公告)号：US20200061177A1

公开(公告)日：2020-02-27

申请号：US16534457

申请日：2019-08-07

Applicant: Pfizer Inc.

Inventor： Robert G.K. Donald ,  Annaliesa Sybil Anderson ,  Laurent Oliver Chorro ,  Jianxin Gu ,  Jin-Hwan Kim ,  Srinivas Kodali ,  Jason Arnold Lotvin ,  Justin Keith Moran ,  Rosalind Pan ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Suddham Singh ,  Ling Chu ,  Scott Ellis Lomberk ,  Karen Kiyoko Takane ,  Nishith Merchant ,  Wei Chen

IPC: A61K39/108 ,  C08B37/00 ,  A61P37/04 ,  A61P31/04

Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

公开(公告)号：US12128095B2

公开(公告)日：2024-10-29

申请号：US17672126

申请日：2022-02-15

Applicant: Pfizer Inc.

Inventor： Robert G. K. Donald ,  Annaliesa Sybil Anderson ,  Laurent Oliver Chorro ,  Jianxin Gu ,  Jin-Hwan Kim ,  Srinivas Kodali ,  Jason Arnold Lotvin ,  Justin Keith Moran ,  Rosalind Pan ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Suddham Singh ,  Ling Chu ,  Scott Ellis Lomberk ,  Karen Kiyoko Takane ,  Nishith Merchant ,  Wei Chen

IPC: A61K39/108 ,  A61K39/00 ,  A61P31/04 ,  A61P37/04 ,  C08B37/00

CPC classification number: A61K39/0258 ,  A61P31/04 ,  A61P37/04 ,  C08B37/006 ,  A61K2039/6037 ,  A61K2039/627

Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

公开(公告)号：US20230000966A1

公开(公告)日：2023-01-05

申请号：US17772610

申请日：2020-10-28

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Ye Che ,  Wei Chen ,  Laurent Oliver Chorro ,  Ling Chu ,  Robert G.K. Donald ,  Matthew Curtis Griffor ,  Jianxin Gu ,  Zeqiang Guan ,  Jin-Hwan Kim ,  Srinivas Kodali ,  Scott Ellis Lomberk ,  Jason Arnold Lotvin ,  Nishith Merchant ,  Justin Keith Moran ,  Rosalind Pan ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Suddham Singh ,  David Robert Stead ,  Karen Kiyoko Takane

IPC: A61K39/108 ,  C07K14/245

Abstract: In one aspect, the invention relates to a polypeptide derived from E. coli and a fragment thereof, including compositions and methods thereof. Also disclosed herein are compositions that include a polypeptide derived from E. coli and a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. In a further aspect, disclosed herein are mammalian host cells that include sequence(s) encoding a polypeptide derived from E. coli or fragments thereof.

公开(公告)号：US20220152181A1

公开(公告)日：2022-05-19

申请号：US17509110

申请日：2021-10-25

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Laurent Oliver Chorro ,  Robert George Konrad Donald ,  Jacqueline Marie Lypowy ,  Rosalind Pan

IPC: A61K39/108 ,  A61P31/04 ,  A61P37/04

Abstract: This invention relates to compositions that include a polypeptide derived from E. coli or a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof, and methods of use thereof.

公开(公告)号：US11260119B2

公开(公告)日：2022-03-01

申请号：US16534457

申请日：2019-08-07

Applicant: Pfizer Inc.

Inventor： Robert G. K. Donald ,  Annaliesa Sybil Anderson ,  Laurent Oliver Chorro ,  Jianxin Gu ,  Jin-Hwan Kim ,  Srinivas Kodali ,  Jason Arnold Lotvin ,  Justin Keith Moran ,  Rosalind Pan ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Suddham Singh ,  Ling Chu ,  Scott Ellis Lomberk ,  Karen Kiyoko Takane ,  Nishith Merchant ,  Wei Chen

IPC: A61K39/108 ,  C08B37/00 ,  A61P31/04 ,  A61P37/04 ,  A61K39/00

Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.